What is Synthio Labs?
Synthio Labs operates at the intersection of artificial intelligence and healthcare, providing a clinical-grade conversational voice AI platform designed specifically for life sciences organizations. By deploying sophisticated tools such as Jarvis, Ather, and Simulation Studio, the company enables pharmaceutical and biotech teams to facilitate secure, compliant, and intelligent interactions with both clinicians and patients. Headquartered in the San Francisco Bay Area with a global operational footprint, Synthio Labs addresses the critical need for omnichannel engagement in highly regulated environments, ensuring that digital health initiatives remain both scalable and medically accurate.
How much funding has Synthio Labs raised?
Synthio Labs has raised a total of $5M across 1 funding round:
Seed
$5M
Seed (2025): $5M with participation from 1984 Ventures, Elevation Capital, Y Combinator, and Peak XV Partners
Key Investors in Synthio Labs
Peak XV Partners
Peak XV Partners is a prominent venture capital firm that provides strategic support and capital to technology companies across Asia, focusing on sectors like healthcare technology and software.
Elevation Capital
Elevation Capital is a long-standing investment firm that partners with audacious founders, offering deep domain expertise in enterprise AI and healthcare to help startups scale effectively.
Y Combinator
Y Combinator is a premier startup accelerator and seed funding provider that supports early-stage companies through mentorship and access to a vast network of industry leaders.
What's next for Synthio Labs?
The infusion of capital will likely accelerate the company's product roadmap, focusing on deeper integration within global healthcare workflows and the expansion of its AI-driven simulation capabilities. As Synthio Labs transitions into a more mature phase of enterprise-level scaling, the focus will shift toward enhancing regulatory compliance features and broadening its reach across international markets. By leveraging its strong backing from institutional investors, the company is well-positioned to define the next generation of patient-clinician interaction, setting a new standard for digital health communication in the pharmaceutical industry.
See full Synthio Labs company page
